TY - JOUR
T1 - Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial)
T2 - study design
AU - Qayyum, Abbas Ali
AU - Haack-Sørensen, Mandana
AU - Mathiasen, Anders Bruun
AU - Jørgensen, Erik
AU - Ekblond, Annette
AU - Kastrup, Jens
PY - 2012
Y1 - 2012
N2 - Adipose tissue represents an abundant, accessible source of multipotent adipose-derived stromal cells (ADSCs). Animal studies have suggested that ADSCs have the potential to differentiate in vivo into endothelial cells and cardiomyocytes. This makes ADSCs a promising new cell source for regenerative therapy to replace injured tissue by creating new blood vessels and cardiomyocytes in patients with chronic ischemic heart disease. The aim of this special report is to review the present preclinical data leading to clinical stem cell therapy using ADSCs in patients with ischemic heart disease. In addition, we give an introduction to the first-in-man clinical trial, MyStromalCell Trial, which is a prospective, randomized, double-blind, placebo-controlled study using culture-expanded ADSCs obtained from adipose-derived cells from abdominal adipose tissue and stimulated with VEGF-A(165) the week before treatment.
AB - Adipose tissue represents an abundant, accessible source of multipotent adipose-derived stromal cells (ADSCs). Animal studies have suggested that ADSCs have the potential to differentiate in vivo into endothelial cells and cardiomyocytes. This makes ADSCs a promising new cell source for regenerative therapy to replace injured tissue by creating new blood vessels and cardiomyocytes in patients with chronic ischemic heart disease. The aim of this special report is to review the present preclinical data leading to clinical stem cell therapy using ADSCs in patients with ischemic heart disease. In addition, we give an introduction to the first-in-man clinical trial, MyStromalCell Trial, which is a prospective, randomized, double-blind, placebo-controlled study using culture-expanded ADSCs obtained from adipose-derived cells from abdominal adipose tissue and stimulated with VEGF-A(165) the week before treatment.
U2 - 10.2217/rme.12.17
DO - 10.2217/rme.12.17
M3 - Journal article
C2 - 22594332
SN - 1746-0751
VL - 7
SP - 421
EP - 428
JO - Regenerative Medicine
JF - Regenerative Medicine
IS - 3
ER -